Aktiesnakken — December 2009
-
det er en interessant diskussion men jeg har bare meget på tallerknen idag. Vi tales guys
-
Piper Jaffray hæver sin anbefaling af Genmab-aktien til "neutral" fra
"undervægt". -
what?
-
why?
-
pas
-
link?
-
Samtidigt nyfastsætter Piper Jaffray sit kursmål for aktien til 105 kr. pr.
aktie fra 111 kr. pr. aktie. -
der står ikke mere aka... det er fra RBB
-
-
men de har historien fra bloomberg
-
fantastisk. Roche lukker et forsøg og de sætter kursmålet op....
-
også rimeligt flot at have neutral på potentiale 40%
-
er der nogen der kan finde historien på bloomberg?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
